Previous close | 240.13 |
Open | 239.28 |
Bid | 238.14 x 900 |
Ask | 238.35 x 800 |
Day's range | 237.44 - 244.56 |
52-week range | 161.65 - 275.00 |
Volume | |
Avg. volume | 536,572 |
Market cap | 12.279B |
Beta (5Y monthly) | 1.41 |
PE ratio (TTM) | 25.85 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.